uniQure Announces Type A Meeting Scheduled with FDA

Core Viewpoint - uniQure N.V. is advancing its investigational gene therapy AMT-130 for Huntington's disease and has scheduled a Type A meeting with the FDA to discuss the Biologics License Application (BLA) data package for accelerated approval [1][2] Company Overview - uniQure is a leading gene therapy company focused on delivering transformative therapies for patients with severe medical needs, including Huntington's disease, refractory temporal lobe epilepsy, ALS, and Fabry disease [3] - The company has achieved a significant milestone with the approval of its gene therapy for hemophilia B, marking a historic achievement in genomic medicine [3] Regulatory Engagement - The CEO of uniQure expressed optimism about the upcoming discussion with the FDA, highlighting the urgent need for disease-modifying therapies in the Huntington's disease community [2] - The company plans to provide a regulatory update following the receipt of official meeting minutes from the FDA [2]